Image-guided Thermal Laser Ablation Technology in Urology
MR-Guided Laser Ablation may offer advantages in minimizing tumor recurrence and enhancing safety near critical structures during ablation of tumors in the prostate.
A Typical Urology Procedure
Magnetic Resonance Imaging (MRI) is used to help the physician guide the laser applicator to the target tissue. MRI is also used to look for temperature-sensitive changes in the tissue. This allows the physician to see the tissue heating up while they apply laser energy and control how much energy is delivered. The entire procedure generally takes from 1.5 to 3 hours.
![]() |
Patient undergoes MRI scan of the prostate to identify individual tumor(s).
Often, a biopsy needle is placed into the tumor using minimally invasive techniques to confirm diagnosis. |
![]() |
The thin (1.6mm) Visualase laser probe is then placed into the tumor under MRI guidance using minimally invasive techniques. |
![]() |
Pre-procedure MRI confirms placement of applicator in the target tissue. |
![]() |
The laser is activated to begin heating of the tumor. Using MR images and Visualase software allows the physician to see the tissue heating during laser irradiation, and control how much energy is delivered. |
|
|
Results are confirmed with MR images. The laser applicator is removed and the small incision is closed with one stitch and or a bandage. The entire procedure lasts approximately 1.5 to 3 hours, and often requires only mild conscious sedation or even just local anesthetic. Patient often returns home the same day with no catheter.
|
Visualase Technology
Visualase utilizes laser-induced interstitial thermal therapy (LITT).
For more information on LITT and the Visualase Laser Technology visit our technology section.
For prostate focal ablation questions,
please use our Urology Inquiry Form.
A patient’s case is always specific to them and must be discussed with their treating physician as to what may be appropriate an treatment for them. If in doubt, the patient should consider a second or third opinion.






FDA Statement